The firm is committing resources to lead in secure, legal, U.S.-based peptide production and distribution, placing itself to assist patients and providers as an FDA advisory panel indicates expanding legal routes for compounded peptides.

1Elevan Biopharmaceuticals, Inc. ("1Elevan Bio"), an emerging 503A compounding pharmacy headquartered in Fishers, Indiana, is directing substantial resources toward the systems required to become the reliable partner for patients and providers pursuing peptide therapeutics. The company is advancing an integrated model that spans domestic API production through pharmacy dispensing and ongoing tracking of patient results along with adverse events.

This expansion occurs as the U.S. Food and Drug Administration's Pharmacy Compounding Advisory Committee (PCAC) reviewed seven peptides during its July 23-24, 2026 meeting for potential inclusion on the list of bulk drug substances allowable for pharmacies compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. The Committee endorsed adding six peptides (BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax) and rejected Emideltide, addressing all four substances referenced in 1Elevan Bio's public comment submitted to the docket on July 9, 2026.

"Our priority remains ensuring patients and providers can rely on a consistent partner over time," said Darrin Carrico, President and CEO of 1Elevan Bio. "Prescribers are inquiring about these substances directly, and patients are already pursuing them. We have therefore focused on establishing rigorous, compliance-oriented manufacturing and pharmacy operations so that when demand arises for both continuity and a secure, legal source, we stand ready to provide it."

The scope of investment beyond core compounding reflects 1Elevan Bio's dedication to supporting the full patient experience. This involves securing American production, collaborating with providers, and making customized medicines available to patients. The integrated value-chain strategy sets the company apart while aligning with the leadership team's background in patient empowerment.

"Many organizations in this field concentrate on a single segment such as manufacturing, pharmacy services, or telehealth access," Carrico said. "We are building across the complete process because that is essential to achieving top-tier standards: domestic supply, licensed pharmacy dispensing, and real-world data on performance. This is the level of quality we believe patients and providers should expect, and we are constructing operations to deliver it."

The Committee's recommendation does not alter current lawful compounding practices at any pharmacy. Its votes serve in an advisory capacity and are not binding on the FDA. Pharmacies cannot compound these substances until final rules are established through notice-and-comment rulemaking.

1Elevan Bio has expressed willingness to assist the Committee and the FDA as the agency evaluates appropriate conditions for use and intends to remain active in the rulemaking process.

About 1Elevan Biopharmaceuticals

Established in 2022, 1Elevan Bio is advancing healthcare via integrated therapeutics and novel care models. It offers FDA-compliant peptides, specialized compounding, hormone replacement therapies, and solid organ transplant treatments. The company merges pharmacy operations with planned cGMP manufacturing to broaden safe, provider-directed access to quality therapeutics based on verified sourcing, structured compliance, and sustained domestic commitment. Its emphasis on precision medicine and advanced delivery systems is reshaping disease treatment through improved efficacy, stronger safety profiles, and enhanced patient results.